발레리안 (쥐오줌풀)
Valerian Root
📚 관련 논문 (14편)
1. Drug Metab Dispos. 2020 Oct;48(10):1084-1091. doi: 10.1124/dmd.120.000033. Epub 2020 Jul 27. Application of Cryopreserved Human Intestinal Mucosa and Cryopreserved Human Enterocytes in the Evaluation of Herb-Drug Interactions: Evaluation of CYP3A Inhibitory Potential of Grapefruit Juice and C
2. Psychiatr Pol. 2013 May-Jun;47(3):487-98. [Interactions between synthetic drugs used in treatment of selected central nervous system disorders and dietary supplements and herbal drugs]. [Article in Polish] Zabłocka-Słowińska K(1), Jawna K, Biernat J. Author information: (1)Katedra i Zakład B
3. J Altern Complement Med. 2021 Nov;27(11):940-958. doi: 10.1089/acm.2021.0135. Epub 2021 Aug 9. Dietary Supplement Ingredients for Optimizing Cognitive Performance Among Healthy Adults: A Systematic Review. Crawford C(1)(2), Boyd C(1)(2), Deuster PA(1). Author information: (1)Consortium for H
4. J Evid Based Integr Med. 2020 Jan-Dec;25:2515690X20967323. doi: 10.1177/2515690X20967323. Valerian Root in Treating Sleep Problems and Associated Disorders-A Systematic Review and Meta-Analysis. Shinjyo N(1)(2), Waddell G(3), Green J(4). Author information: (1)Department of Infection and Hos
1. Phytother Res. 2019 Apr;33(4):939-948. doi: 10.1002/ptr.6286. Epub 2019 Jan 10. Valerian extract alters functional brain connectivity: A randomized double-blind placebo-controlled trial. Roh D(1)(2), Jung JH(1)(2), Yoon KH(1), Lee CH(1)(2), Kang LY(1)(2), Lee SK(1)(2), Shin K(1), Kim DH(1)(2). Author information: (1)Department of Psychiatry, Hallym University College of Medicine, Chuncheon, Korea. (2)Mind-neuromodulation Laboratory, Hallym University College of Medicine, Chuncheon, Korea. Valerian root is the most commonly used herbal supplement for sedation and anxiolysis, but it is unknown whether it may affect functional brain connectivity. Our goal was to use electroencephalography (EEG) to investigate whether valerian root extract (VRE) affects resting-state connectivity changes and whether such changes are associated with clinical symptoms. This 4-week, double-blinded, randomized, placebo-controlled clinical trial was conducted with 64 nonclinical volunteers suffering psychological stress. The participants received VRE (100 mg) or a placebo thrice daily. We examined VRE's therapeutic effects on anxiety and stress-related psychological constructs. Functional brain connectivity changes were measured as EEG coherence in the alpha and theta frequency bands. The VRE and placebo groups both exhibited significant postintervention improvements on all clinical scales, but no significant between-group differences in these changes were noted. Compared with the placebo group, the VRE group exhibited significantly greater increases in frontal brain region alpha coherence across four electrode pairs, and these changes were significantly correlated with anxiolysis. The VRE group also exhibited significantly greater decreases in theta coherence across another four electrodes pairs. Our findings indicate that VRE alters functional brain connectivity in relation to anxiety. Further EEG studies are needed to confirm VRE's neurophysiological effects. © 2019 John Wiley & Sons, Ltd. DOI: 10.1002/ptr.6286 PMID: 30632220 [Indexed for MEDLINE]
2. Cultur Divers Ethnic Minor Psychol. 2000 Feb;6(1):84-92. doi: 10.1037/1099-9809.6.1.84. Valerian as a hypnotic for Hispanic patients. Dominguez RA(1), Bravo-Valverde RL, Kaplowitz BR, Cott JM. Author information: (1)Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Florida 33136, USA. Valerian is a botanical used for its sedative effects whose central nervous system activity is ascribed to multiple constituents. Twenty-three established outpatient symptomatic Hispanic volunteers receiving mental health services at a large urban hospital participated in this case study. All complained of insufficient sleep. They were asked to try a popular national brand of valerian ("Nature's Way", 470 mg valerian root) and completed sleep questionnaires at baseline and at the end of Weeks 1 and 2. They were instructed to take 1 capsule each night before retiring and were allowed to increase their dose to a maximum of 3 capsules after Week 1. Twenty patients completed the trial. On an ordinal scale of 1 (no effect), 3 (moderately helpful), and 5 (extremely helpful), 16 patients rated their insomnia as at least "moderately improved" at the end of Week 1. By Week 2, 16 still rated themselves at least "moderately improved," but 15 of them now described their response as either a 4 or a 5. Global improvement at Week 2 was significantly better than at Week 1 (Wilcoxon ranks test p = .005), perhaps reflecting a time-dependent or dose-response relationship. This case study suggests that valerian can be a supplement for improving insomnia in a symptomatic population. DOI: 10.1037/1099-9809.6.1.84 PMID: 10975170 [Indexed for MEDLINE]
3. J Am Nutr Assoc. 2024 Feb;43(2):167-182. doi: 10.1080/27697061.2023.2244031. Epub 2023 Aug 10. The Role of Dietary Ingredients in Mental Energy - A Scoping Review of Randomized Controlled Trials. Nieman KM(1), Zhu Y(2), Tucker M(2), Koecher K(2). Author information: (1)Katalyses, Ankeny, Iowa, USA. (2)Bell Institute of Health and Nutrition, General Mills, Inc, Minneapolis, Minnesota, USA. Low mental energy can contribute to decreased productivity, altered life balance, decreased physical performance, and ultimately affect quality of life. As such, there is a great demand for food and beverage products that positively impact mental energy. Numerous products claim to alter mental energy making continued review of the scientific evidence critical. The objective of this study was to conduct a scoping review of randomized controlled trials to evaluate the effect of 18 dietary ingredients on mental energy outcomes in adults without severe disease. Methods: A literature search, completed using PubMed, resulted in the identification of 2261 articles, 190 of which met eligibility from initial abstract review. Full-text review was completed on the 190 studies which resulted in 101 articles that fully met eligibility for inclusion in this study. The search strategy for two ingredients did not yield any eligible studies, leaving studies for 16 ingredients that were extracted and summarized by reported significantly improved outcomes for cognition, mood and perceived feelings, and sleep assessments. The preliminary results for several dietary ingredients directionally suggested a mental energy benefit (≥20% of outcomes), including ashwagandha, chamomile, dark chocolate, ginseng, green tea, lavender, lion's mane mushroom, maca, tart cherries, turmeric, and valerian root. The results of this scoping review suggest that of the 16 dietary ingredients reviewed, 11 may be promising for further exploration on their potential benefits in supporting mental energy. Given consumer demand and market growth for food and beverage products that positively impact mental energy; continued efforts in assessment method alignment and additional evaluation in well-designed trials is warranted.KEY TEACHING POINTSOf the 16 dietary ingredients reviewed, 11 (ashwagandha, chamomile, dark chocolate, ginseng, green tea, lavender, lion's mane mushroom, maca, melatonin foods, turmeric, and valerian root) may be promising for further exploration on their potential mental energy benefits.Dark chocolate, ginseng, ashwagandha, and lion's mane mushroom were the most promising ingredients for further evaluation in the cognition domain of the ingredients evaluated.Turmeric, maca, lavendar, and ashwagandha were the most promising ingredients for further evaluation in the mood and perceived feelings domain of the ingredients evaluated.Ashwagandha, chamomile, green tea, melatonin foods, valerian root were the most promising ingredients for further evaluation in the sleep domain of the ingredients evaluated.Additional, well-designed, consistent, clinical trials and systematic reviews are warranted as the challenge of heterogeneity in mental energy study design remains. DOI: 10.1080/27697061.2023.2244031 PMID: 37561965 [Indexed for MEDLINE]
4. Chin J Integr Med. 2021 Jan;27(1):7-15. doi: 10.1007/s11655-020-2727-1. Epub 2021 Jan 8. Efficacy of Valerian Extract on Sleep Quality after Coronary Artery bypass Graft Surgery: A Triple-Blind Randomized Controlled Trial. Zare Elmi HK(1), Gholami M(2), Saki M(3), Ebrahimzadeh F(4). Author information: (1)Student Research Committee, Lorestan University of Medical Sciences, Khorramabad, 6814993165, Iran. (2)School of Nursing and Midwifery, Lorestan University of Medical Sciences, Khorramabad, 6814993165, Iran. mohammad13565@yahoo.com. (3)Social Determinants of Health Research Center, Lorestan University of Medical Sciences, Khorramabad, 6814993165, Iran. (4)Department of Biostatistics and Epidemiology, School of Health and Nutrition, Lorestan University of Medical Sciences, Khorramabad, 6814993165, Iran. OBJECTIVE: To assess the effect of valerian root extract on the sleep quality of patients after coronary artery bypass graft (CABG) surgery. METHODS: The patients who participated in this triple-blind clinical trial were selected by permuted block randomization. The participants were assigned to the valerian (n=36) and placebo (n=36) groups. The valerian group received 530 mg of valerian capsules for 30 nights after CABG surgery, and the placebo group received 530 mg of the placebo capsules containing wheat flour. The Pittsburgh Sleep Quality Index (PSQI), the prothrombin time (PT) and partial thromboplastin time (PTT) were assessed on four occasions, including the baseline, the 3rd, 14th and 30th days following intervention. RESULTS: The odds ratio of worsened sleep quality significantly varied over time (the interaction of time and group) in the valerian group compared to the placebo group in various dimensions including total sleep quality (P=0.001), sleep latency (P<0.01), sleep duration (P=0.020), sleep efficiency (P=0.001) and daytime dysfunction (P=0.025). No significant difference was observed in the alterations of the odds ratio of PT in the two groups over time. (P=0.371). CONCLUSION: The consumption of oral valerian root extract over 30 nights could significantly improve the patients' sleep quality safely after CABG surgery. DOI: 10.1007/s11655-020-2727-1 PMID: 33420602 [Indexed for MEDLINE]
5. Psychopharmacology (Berl). 2015 Mar;232(5):843-50. doi: 10.1007/s00213-014-3716-x. Epub 2014 Aug 31. Can Valeriana officinalis root extract prevent early postoperative cognitive dysfunction after CABG surgery? A randomized, double-blind, placebo-controlled trial. Hassani S(1), Alipour A, Darvishi Khezri H, Firouzian A, Emami Zeydi A, Gholipour Baradari A, Ghafari R, Habibi WA, Tahmasebi H, Alipour F, Ebrahim Zadeh P. Author information: (1)Department of Nursing, Faculty of Medicine, Islamic Azad University, 7th km of Sea Road (Farah Abaad), Firoozkande, Sari, Iran. RATIONALE: We hypothesized that valerian root might prevent cognitive dysfunction in coronary artery bypass graft (CABG) surgery patients through stimulating serotonin receptors and anti-inflammatory activity. OBJECTIVES: The aim of this study was to evaluate the effect of Valeriana officinalis root extract on prevention of early postoperative cognitive dysfunction after on-pump CABG surgery. METHODS: In a randomized, double-blind, placebo-controlled trial, 61 patients, aged between 30 and 70 years, scheduled for elective CABG surgery using cardiopulmonary bypass (CPB), were recruited into the study. Patients were randomly divided into two groups who received either one valerian capsule containing 530 mg of valerian root extract (1,060 mg/daily) or placebo capsule each 12 h for 8 weeks, respectively. For all patients, cognitive brain function was evaluated before the surgery and at 10-day and 2-month follow-up by Mini Mental State Examination (MMSE) test. RESULTS: Mean MMSE score decreased from 27.03 ± 2.02 in the preoperative period to 26.52 ± 1.82 at the 10th day and then increased to 27.45 ± 1.36 at the 60th day in the valerian group. Conversely, its variation was reduced significantly after 60 days in the placebo group, 27.37 ± 1.87 at the baseline to 24 ± 1.91 at the 10th day, and consequently slightly increased to 24.83 ± 1.66 at the 60th day. Valerian prophylaxis reduced odds of cognitive dysfunction compared to placebo group (OR = 0.108, 95 % CI 0.022-0.545). CONCLUSION: We concluded that, based on this study, the cognitive state of patients in the valerian group was better than that in the placebo group after CABG; therefore, it seems that the use of V. officinalis root extract may prevent early postoperative cognitive dysfunction after on-pump CABG surgery. DOI: 10.1007/s00213-014-3716-x PMID: 25173770 [Indexed for MEDLINE]
6. J Complement Integr Med. 2011 Oct 11;8. doi: 10.2202/1553-3840.1465. Extract of valerian root (Valeriana officinalis L.) vs. placebo in treatment of obsessive-compulsive disorder: a randomized double-blind study. Pakseresht S(1), Boostani H(1), Sayyah M(1). Author information: (1)Jundishapur University of Medical Sciences. OBJECTIVE: Obsessive-Compulsive Disorder (OCD) is a common neuropsychiatric condition. Many herbs with psychotropic effects exist which can have fewer side effects compared to more conventional medications. Valeriana Officinalis L. is a well-known medicinal plant with a long history of usage in the world with an effect on GABA. This plant is reported to be safe on humans. Our objective in this study was to compare the efficacy of the extract of Valeriana Officinalis L. with placebo in the treatment of OCD. METHODS: The study was an 8-week pilot double-blind randomized trial. Thirty-one adult outpatients who met the DSM-IV-TR criteria for OCD based on the structured clinical interview participated in the trial. In this double-blind and randomized trial, patients were randomly assigned to receive either capsule of the extract (765 mg/day) or placebo (30 mg/day) for 8 weeks. RESULTS: The results showed significant difference between the extract and placebo in the end of treatment (P=0.000). Somnolence was the only significant difference between the two groups in terms of observed side effects (P=0.02). CONCLUSION: The results suggest that Valeriana Officinalis L. has some antiobsessive and compulsive effects. However, further studies are needed to confirm these findings. Psychiatrists often find that many patients cannot tolerate the side effects of psychiatry medicine Valeriana Officinalis L. is a well-known medicinal plant with a long history of usage in world with effect on GABA.The results showed significant difference between the extract and placebo in the treatment of OCD. There was also no significant difference between the two groups in terms of observed side effects. DOI: 10.2202/1553-3840.1465 PMID: 22718671 [Indexed for MEDLINE]
7. Phytother Res. 2009 Sep;23(9):1303-8. doi: 10.1002/ptr.2771. Fixed herbal drug combination with and without butterbur (Ze 185) for the treatment of patients with somatoform disorders: randomized, placebo-controlled pharmaco-clinical trial. Melzer J(1), Schrader E, Brattström A, Schellenberg R, Saller R. Author information: (1)Institute of Complementary Medicine, Department for Internal Medicine, University Hospital Zurich, Switzerland. joerg.melzer@usz.ch Herbal drugs are often used in patients with somatoform disorders yet, the available evidence is limited. The aim of the present short-term study was to evaluate in a pharmaco-clinical trial the additional benefit of butterbur in a fixed herbal drug combination (Ze 185 = 4-combination versus 3-combination without butterbur and placebo) in patients with somatoform disorders.For a 2-week treatment in patients with somatization disorder (F45.0) and undifferentiated somatoform disorder (F45.1), 182 patients were randomized for a 3-arm trial (butterbur root, valerian root, passionflower herb, lemon balm leaf versus valerian root, passionflower herb, lemon balm leaf versus placebo). Anxiety (visual analogue scale - VAS) and depression (Beck's Depression Inventory - BDI) served as primary parameters, Clinical Global Impression (CGI) was a secondary parameter.The 4-combination was significantly superior to the 3-combination and placebo (4-combination > 3-combination > placebo) in all the primary and secondary parameters (PP-population). Analysis of the ITT population confirmed these results. As to safety, no serious adverse events occurred. In total 9 non-serious adverse events were documented but the distribution did not differ significantly between the treatment groups.This herbal preparation (Ze185) showed to be an efficacious and safe short-term treatment in patients with somatoform disorders. DOI: 10.1002/ptr.2771 PMID: 19274698 [Indexed for MEDLINE]
8. Pharmacopsychiatry. 1999 Nov;32(6):235-41. doi: 10.1055/s-2007-991100. The influence of valerian treatment on "reaction time, alertness and concentration" in volunteers. Kuhlmann J(1), Berger W, Podzuweit H, Schmidt U. Author information: (1)Lichtwer Pharma AG, Berlin, Germany. jkuhlmann@csi.com A randomised, controlled, double-blind trial was performed on 102 male and female volunteers to determine whether reaction time, alertness and concentration might be impaired by treatment with a native valerian root extract (VRE). The effect was first examined the morning after a single evening dose of VRE (600 mg LI 156) vs. flunitrazepam (FNZ) (1 mg) and placebo (PL) (trial section A), and then after two weeks of evening administration of VRE (600 mg LI 156) vs. PL (trial section B). 99 volunteers were analysed in section A and 91 in section B. The primary criterion was the median of reaction time (MRT) measured with the Vienna Determination Test. Secondary criteria were cognitrones (alertness test), tracking test (two-handed co-ordination), sleep quality (VIS-A, Vis-M), further VDT parameters, and safety criteria. The single administration of LI 156 did not impair the reaction abilities, concentration and co-ordination. After 14 days of treatment, the equivalence of VRE and PL was proven by confirmative analysis concerning the improvement of MRT (p = 0.4481). Evaluation of the secondary criteria were consistent with the results of the primary criterion. It is concluded that neither single nor repeated evening administrations of 600 mg of VRE have a relevant negative impact on reaction time, alertness and concentration the morning after intake. DOI: 10.1055/s-2007-991100 PMID: 10599933 [Indexed for MEDLINE]
9. Psychopharmacology (Berl). 1985;87(4):406-9. doi: 10.1007/BF00432503. Effect of valerian on human sleep. Balderer G, Borbély AA. The effect of an aqueous extract of valerian root on sleep was studied in two groups of healthy, young subjects. One group (N = 10) slept at home, the other (N = 8) in the sleep laboratory. Sleep was evaluated on the basis of questionnaires, self-rating scales and night-time motor activity. In addition, polygraphic sleep recordings and spectral analysis of the sleep EEG was performed in the laboratory group. Under home conditions, both doses of valerian extract (450 and 900 mg) reduced perceived sleep latency and wake time after sleep onset. Night-time motor activity was enhanced in the middle third of the night and reduced in the last third. The data suggest a dose-dependent effect. In the sleep laboratory, where only the higher dose of valerian was tested, no significant differences from placebo were obtained. However, the direction of the changes in the subjective and objective measures of sleep latency and wake time after sleep onset, as well as in night-time motor activity, corresponded to that observed under home conditions. There was no evidence for a change in sleep stages and EEG spectra. The results indicate that the aqueous valerian extract exerts a mild hypnotic action. DOI: 10.1007/BF00432503 PMID: 3936097 [Indexed for MEDLINE]
10. Pharmacol Biochem Behav. 1982 Jul;17(1):65-71. doi: 10.1016/0091-3057(82)90264-7. Aqueous extract of valerian root (Valeriana officinalis L.) improves sleep quality in man. Leathwood PD, Chauffard F, Heck E, Munoz-Box R. The effect of an aqueous extract of valerian (Valeriana officinalis L.) root on subjectively rated sleep measures was studied on 128 people. Each person received 9 samples to test (3 containing placebo, 3 containing 400 mg valerian extract and 3 containing a proprietary over-the-counter valerian preparation). The samples, identified only by a code number, and presented in random order, were taken on non-consecutive nights. Valerian produced a significant decrease in subjectively evaluated sleep latency scores and a significant improvement in sleep quality: the latter was most notable among people who considered themselves poor or irregular sleepers, smokers, and people who thought they normally had long sleep latencies. Night awakenings, dream recall and somnolence the next morning were relatively unaffected by valerian. With the proprietary valerian-containing preparation, the only change was a significant increase in reports of feeling more sleepy than normal the next morning. Thus the questionnaire, simple to use and non-invasive, provides a sensitive means for detecting the effects of mild sedatives on different aspects of sleep in man. It also allows identification within the test population of the subgroups most affected. DOI: 10.1016/0091-3057(82)90264-7 PMID: 7122669 [Indexed for MEDLINE]
⚠️ 면책 고지
이 정보는 일반 교육 목적이며 의료 진단/처방을 대체하지 않습니다.